Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica–Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer-Reference-Cited by-同舟云学术

Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica–Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer

Published:2018-05-22 Issue:7 Volume:15 Page:2698-2713
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Kumar B. N. Prashanth¹,Puvvada Nagaprasad²,Rajput Shashi³,Sarkar Siddik⁴^ORCID,Mahto Madhusudan Kr.,Yallapu Murali M.¹,Pathak Amita^ORCID,Emdad Luni⁴,Das Swadesh K.⁴,Reis Rui L.⁵,Kundu S. C.⁵^ORCID,Fisher Paul B.⁴,Mandal Mahitosh^ORCID

Affiliation:

1. Department of Pharmaceutical Sciences and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee 38163, United States

2. Chemical Biology, CSIR-Indian Institute of Chemical Technology, Uppal Road, Hyderabad 500007, India

3. Tumor Initiation and Maintenance, Sanford-Burnham Medical Research Institute, La Jolla, California 92037, United States

4. Department of Human and Molecular Genetics, VCU Institute of Molecular Genetics, VCU Massey Cancer, Virginia Commonwealth University, School of Medicine, Richmond, Virginia 23298, United States

5. 3Bs Research Group, Headquarters of the European Institute of Excellence on Tissue Engineering and Regenerative Medicine, University of Minho, Avepark-4805-017, Barco, Guimaraes, Portugal

Funder

Council of Scientific and Industrial Research

Department of Biotechnology , Ministry of Science and Technology

Department of Science and Technology, Ministry of Science and Technology

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.8b00218

Reference80 articles.

1. Tamoxifen in the Treatment of Breast Cancer